{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:25:32Z","timestamp":1780964732671,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,22]],"date-time":"2012-12-22T00:00:00Z","timestamp":1356134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s10928-012-9286-9","type":"journal-article","created":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T08:38:19Z","timestamp":1356079099000},"page":"53-65","source":"Crossref","is-referenced-by-count":15,"title":["Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator"],"prefix":"10.1007","volume":"40","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Schneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Bue-Valleskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwee Poo","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heathman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,22]]},"reference":[{"issue":"3","key":"9286_CR1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11892-005-0005-4","volume":"5","author":"FM Matschinsky","year":"2005","unstructured":"Matschinsky FM (2005) Glucokinase, glucose homeostasis, and diabetes mellitus. Curr Diab Rep 5(3):171\u2013176","journal-title":"Curr Diab Rep"},{"issue":"Pt 12","key":"9286_CR2","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1242\/jeb.00241","volume":"206","author":"JE Wilson","year":"2003","unstructured":"Wilson JE (2003) Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206(Pt 12):2049\u20132057","journal-title":"J Exp Biol"},{"issue":"1","key":"9286_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00018-008-8322-9","volume":"66","author":"PB Iynedjian","year":"2009","unstructured":"Iynedjian PB (2009) Molecular physiology of mammalian glucokinase. Cell Mol Life Sci 66(1):27\u201342","journal-title":"Cell Mol Life Sci"},{"issue":"15","key":"9286_CR4","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2174\/092986706777452551","volume":"13","author":"R Kevin","year":"2006","unstructured":"Kevin R, Guertin JG (2006) Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Curr Med Chem 13(15):1839\u20131843","journal-title":"Curr Med Chem"},{"issue":"17","key":"9286_CR5","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2174\/156802608786413483","volume":"8","author":"J Grimsby","year":"2008","unstructured":"Grimsby J, Berthel SJ, Sarabu R (2008) Glucokinase activators for the potential treatment of type 2 diabetes. Curr Top Med Chem 8(17):1524\u20131532","journal-title":"Curr Top Med Chem"},{"key":"9286_CR6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3410\/M2-43","volume":"2","author":"FM Matschinsky","year":"2010","unstructured":"Matschinsky FM, Porte D (2010) Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000 Med Rep 2:43","journal-title":"F1000 Med Rep"},{"issue":"Suppl 1","key":"9286_CR7","first-page":"A272","volume":"60","author":"JM Bue-Valleskey","year":"2011","unstructured":"Bue-Valleskey JM, Schneck KB, Sinha VP, Wondmagegnehu ET, Kapitza C, Miller JW (2011) LY2599506, a novel glucokinase activator (GKA), improves fasting and postprandial glucose in patients with type 2 diabetes mellitus (T2DM). Diabetes 60(Suppl 1):A272","journal-title":"Diabetes"},{"key":"9286_CR8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev.pharmtox.40.1.67","volume":"40","author":"LB Sheiner","year":"2000","unstructured":"Sheiner LB, Steimer JL (2000) Pharmacokinetic\/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67\u201395","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"9286_CR9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1742-7843.2005.pto960310.x","volume":"96","author":"MO Karlsson","year":"2005","unstructured":"Karlsson MO, Anehall T, Friberg LE, Henningsson A, Kloft C, Sandstrom M, Xie R (2005) Pharmacokinetic\/pharmacodynamic modelling in oncological drug development. Basic Clin Pharmacol Toxicol 96(3):206\u2013211","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"9286_CR10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/clpt.2010.81","volume":"88","author":"SR Allerheiligen","year":"2010","unstructured":"Allerheiligen SR (2010) Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin Pharmacol Ther 88(1):135\u2013137","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"9286_CR11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1208\/s12248-008-9062-3","volume":"10","author":"L Zhang","year":"2008","unstructured":"Zhang L, Pfister M, Meibohm B (2008) Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J 10(4):552\u2013559","journal-title":"AAPS J"},{"issue":"2","key":"9286_CR12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/clpt.2010.114","volume":"88","author":"N Holford","year":"2010","unstructured":"Holford N, Ma SC, Ploeger BA (2010) Clinical trial simulation: a review. Clin Pharmacol Ther 88(2):166\u2013182","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9286_CR13","doi-asserted-by":"crossref","first-page":"E544","DOI":"10.1208\/aapsj070355","volume":"7","author":"JY Chien","year":"2005","unstructured":"Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V (2005) Pharmacokinetics\/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 7(3):E544\u2013E559","journal-title":"AAPS J"},{"issue":"1","key":"9286_CR14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1742-7843.2009.00456.x","volume":"106","author":"SG Dahl","year":"2010","unstructured":"Dahl SG, Aarons L, Gundert-Remy U, Karlsson MO, Schneider YJ, Steimer JL, Troconiz IF (2010) Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework. Basic Clin Pharmacol Toxicol 106(1):2\u201312","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"10","key":"9286_CR15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/0091270007302168","volume":"47","author":"PM Jauslin","year":"2007","unstructured":"Jauslin PM, Silber HE, Frey N, Gieschke R, Simonsson US, Jorga K, Karlsson MO (2007) An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol 47(10):1244\u20131255","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"9286_CR16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-7843.2009.00510.x","volume":"106","author":"HE Silber","year":"2010","unstructured":"Silber HE, Jauslin PM, Frey N, Karlsson MO (2010) An integrated model for the glucose-insulin system. Basic Clin Pharmacol Toxicol 106(3):189\u2013194","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"9286_CR17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/0091270010362536","volume":"51","author":"PM Jauslin","year":"2011","unstructured":"Jauslin PM, Frey N, Karlsson MO (2011) Modeling of 24-hour glucose and insulin profiles of patients with type 2 diabetes. J Clin Pharmacol 51(2):153\u2013164","journal-title":"J Clin Pharmacol"},{"key":"9286_CR18","doi-asserted-by":"crossref","unstructured":"Schneck KB, Zhang X, Bauer R, Karlsson MO, Sinha VP (2012) Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model. J Pharmacokinet Pharmacodyn. doi: 10.1007\/s10928-012-9287-8","DOI":"10.1007\/s10928-012-9287-8"},{"issue":"2","key":"9286_CR19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/clpt.2008.2","volume":"84","author":"B Hamren","year":"2008","unstructured":"Hamren B, Bjork E, Sunzel M, Karlsson M (2008) Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther 84(2):228\u2013235","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"9286_CR20","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1210\/jc.2002-021225","volume":"88","author":"AJ Garber","year":"2003","unstructured":"Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS (2003) Efficacy of glyburide\/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 88(8):3598\u20133604","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"9286_CR21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0168-8227(99)00002-9","volume":"43","author":"T Marbury","year":"1999","unstructured":"Marbury T, Huang WC, Strange P, Lebovitz H (1999) Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 43(3):155\u2013166","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"9286_CR22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2337\/diacare.22.3.463","volume":"22","author":"BH Wolffenbuttel","year":"1999","unstructured":"Wolffenbuttel BH, Landgraf R (1999) A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 22(3):463\u2013467","journal-title":"Diabetes Care"},{"issue":"9","key":"9286_CR23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1055\/s-2007-979831","volume":"28","author":"DG Dills","year":"1996","unstructured":"Dills DG, Schneider J (1996) Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride\/Glyburide Research Group. Horm Metab Res 28(9):426\u2013429. doi: 10.1055\/s-2007-979831","journal-title":"Horm Metab Res"},{"issue":"9131","key":"9286_CR24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837\u2013853","journal-title":"Lancet"},{"issue":"11","key":"9286_CR25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1023\/A:1007574217260","volume":"17","author":"LJ Lesko","year":"2000","unstructured":"Lesko LJ, Rowland M, Peck CC, Blaschke TF (2000) Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 17(11):1335\u20131344","journal-title":"Pharm Res"},{"issue":"6","key":"9286_CR26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1067\/mcp.2001.115455","volume":"69","author":"GR Galluppi","year":"2001","unstructured":"Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW Jr, Peck CC (2001) Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 69(6):387\u2013399","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9286_CR27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1023\/A:1007548719885","volume":"17","author":"PL Bonate","year":"2000","unstructured":"Bonate PL (2000) Clinical trial simulation in drug development. Pharm Res 17(3):252\u2013256","journal-title":"Pharm Res"},{"key":"9286_CR28","doi-asserted-by":"crossref","unstructured":"Kimko HC, Peck CC (eds) (2011) Clinical trial simulation: application and trends. AAPS advances in the pharmaceutical sciences series, vol 1. Springer-Verlag, New York","DOI":"10.1007\/978-1-4419-7415-0"},{"issue":"1","key":"9286_CR29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","volume":"16","author":"R Bruno","year":"1998","unstructured":"Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics\/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187\u2013196","journal-title":"J Clin Oncol"},{"issue":"6","key":"9286_CR30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10928-011-9221-5","volume":"38","author":"M Hasegawa","year":"2011","unstructured":"Hasegawa M, Imai Y, Hiraoka M, Ito K, Roy A (2011) Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 38(6):803\u2013832","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"9286_CR31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10928-009-9146-4","volume":"37","author":"M Marchand","year":"2010","unstructured":"Marchand M, Fuseau E, Critchley DJ (2010) Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation. J Pharmacokinet Pharmacodyn 37(1):99\u2013118","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"9286_CR32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/clpt.2010.54","volume":"88","author":"R Greef de","year":"2010","unstructured":"de Greef R, Zandvliet AS, de Haan AF, Ijzerman-Boon PC, Marintcheva-Petrova M, Mannaerts BM (2010) Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clin Pharmacol Ther 88(1):79\u201387","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"9286_CR33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1067\/mcp.2000.110975","volume":"68","author":"HC Kimko","year":"2000","unstructured":"Kimko HC, Reele SS, Holford NH, Peck CC (2000) Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 68(5):568\u2013577","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"9286_CR34","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.2337\/dc11-s236","volume":"34","author":"FM Matschinsky","year":"2011","unstructured":"Matschinsky FM, Zelent B, Doliba N, Li C, Vanderkooi JM, Naji A, Sarabu R, Grimsby J (2011) Glucokinase activators for diabetes therapy: May 2010 status report. Diabetes Care 34(Suppl 2):S236\u2013S243","journal-title":"Diabetes Care"},{"key":"9286_CR35","volume-title":"Simulation for designing clinical trials: a pharmacokinetic-pharmacodynamic modeling perspective drugs and the pharmaceutical sciences","author":"H Kimko","year":"2003","unstructured":"Kimko H, Duffull SB (2003) Simulation for designing clinical trials: a pharmacokinetic-pharmacodynamic modeling perspective drugs and the pharmaceutical sciences. Marcel Dekker, New York"},{"key":"9286_CR36","volume-title":"Hematology: basic principles and practice","year":"2005","unstructured":"Hoffman R (ed) (2005) Hematology: basic principles and practice. Elsevier Churchill Livingston, Philadelphia"},{"issue":"6","key":"9286_CR37","first-page":"E667","volume":"236","author":"RN Bergman","year":"1979","unstructured":"Bergman RN, Ider YZ, Bowden CR, Cobelli C (1979) Quantitative estimation of insulin sensitivity. Am J Physiol 236(6):E667\u2013E677","journal-title":"Am J Physiol"},{"issue":"5","key":"9286_CR38","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diabetes.48.5.1198","volume":"48","author":"AD Cherrington","year":"1999","unstructured":"Cherrington AD (1999) Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48(5):1198\u20131214","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"9286_CR39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1463-1326.2011.01454.x","volume":"13","author":"CJ Ramnanan","year":"2011","unstructured":"Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD (2011) Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 13(Suppl 1):118\u2013125","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"9286_CR40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1463-1326.2011.01450.x","volume":"13","author":"JN Walker","year":"2011","unstructured":"Walker JN, Ramracheya R, Zhang Q, Johnson PR, Braun M, Rorsman P (2011) Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obes Metab 13(Suppl 1):95\u2013105","journal-title":"Diabetes Obes Metab"},{"key":"9286_CR41","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc08-0545","volume":"31","author":"DM Nathan","year":"2008","unstructured":"Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31:1473\u20131478","journal-title":"Diabetes Care"},{"key":"9286_CR42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2337\/diacare.25.2.275","volume":"25","author":"CL Rohlfing","year":"2002","unstructured":"Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE (2002) Defining the relationship between plasma glucose and HbA1c. Diabetes Care 25:275\u2013278","journal-title":"Diabetes Care"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-012-9286-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-012-9286-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-012-9286-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T21:56:01Z","timestamp":1714773361000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-012-9286-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,22]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["9286"],"URL":"https:\/\/doi.org\/10.1007\/s10928-012-9286-9","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,22]]}}}